| Body na spoluautora | Body za publikaci pro MU | Odkaz ISVaV | | 2,11 | 8,42 | Mikrochimérismus - na hraně počínajícího relapsu AML?
|
| 1,20 | 4,81 | Úloha FLT3 mutací v patogenezi akutní myeloidní leukemie
|
| 43,83 | 87,65 | An atypical junction of BCR-ABL gene as molelcular marker for quantitative monitoring of minimal residual disease in patients with chronic myeloid leukemia (CML)
|
| 29,22 | 87,65 | A novel MGB probe-based assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPMI (nucleophosmin) exon 12 mutations
|
| 0,00 | 0,00 | Charakterizace abnormalit v genech p53 a ATM u B-CLL pacientůbuněk
|
| 9,18 | 128,51 | CHARACTERIZATION OF P53 ABNORMALITIES IN B-CLL PATIENTS IN RELATION TO IGVH MUTATION STATUS AND PREVIOUS TREATMENT
|
| 17,05 | 119,33 | Acute myeloid leukemias with reccurent genetic abnormalities: frequent assessment of minimal residual disease and treatment of molecular relaps with chemotherapy. Acute myeloid leukemias with reccurent genetic abnormalities: frequent assessment of minima
|
| 0,00 | 0,00 | Využití long-oligonucleotide arrayCGH v diagnostice leukémií
|
| 0,00 | 0,00 | Charakterizace abnormalit v genech p53 a ATM u B-CLL pacientů
|
| 1,85 | 20,40 | Identification of somatic hypermutations in the TP53 gene in B-cell chronic lymphocytic leukemia
|
| 0,62 | 5,62 | Má v léčbě akutní lymfoblastické leukemie dospělých místo i autologní transplantace krvetvorných buněk
|
| 14,68 | 88,09 | Expression and potential role of fibroblast growth factor 2 and its receptors in human embryonic stem cells
|
| 6,77 | 20,30 | Fibroblast growth factor signaling in embryonic and cancer stem cells
|
| 16,06 | 128,51 | Detection of molecular relapse of AML by very frequent quantitative monitoring of different molecular markers (Fusion transcripts and WTI) in different compartments (peripheral blood, bone marrow, and selected CD34+bone marrow cells) and its treatment...
|
| 6,67 | 86,67 | Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation
|
| 1,01 | 4,03 | MICROCHIMERISM - LOOK INTO THE INCIPIENT AML RELAPSE?
|
| 0,37 | 2,62 | Srovnání účinnosti čtyř metod pro izolaci aspergilové DNA z periferní krve
|
| 0,00 | 0,00 | Transplantace krvetvorných buněk
|
| 0,81 | 4,03 | Chimerism status as a possible marker of incipient disease relapse in patients with AML
|
| 0,43 | 2,59 | Detekce invazivní aspergilózy pomocí PCR a real-time PCR - přednosti a úskalí
|
| 0,03 | 0,21 | Další chronické lymfatické leukemie
|
| 2,76 | 22,12 | Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: Frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression
|
| 0,00 | 0,00 | Detekce mutace JAK2 V617F u myeloproliferativních onemocnění - přehled a vlastní zkušenosti
|
| 8,87 | 97,59 | A complex role for FGF-2 in self renewal, survival, and adhesion of human embryonic stem cells
|
| 20,03 | 100,15 | A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations
|
| 2,67 | 10,67 | CEBPA Gene mutational status A complete screening using high-resolution melt curve analysis
|
| 4,68 | 14,04 | Stanovení chimérismu pomocí polymerázové řetězové reakce v reálném čase. Přehled a první vlastní zkušennosti
|
Back
(c) Michal Bulant, 2011